Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface by Allison J. Farrand et al.
Only two amino acids are essential for cytolytic toxin
recognition of cholesterol at the membrane surface
Allison J. Farranda, Stephanie LaChapellea, Eileen M. Hotzea, Arthur E. Johnsonb,c, and Rodney K. Twetena,1
aDepartment of Microbiology and Immunology, University of Oklahoma Sciences Center, Oklahoma City, OK 73104; bDepartment of Molecular and Cellular
Medicine, Texas A&M University Health Science Center, College Station, TX 77843-1114; and cDepartments of Chemistry and Biochemistry and Biophysics,
Texas A&M University, College Station, TX 77843
Edited by R. John Collier, Harvard Medical School, Boston, MA, and approved January 21, 2010 (received for review October 7, 2009)
The recognition andbindingof cholesterol is an important featureof
many eukaryotic, viral, and prokaryotic proteins, but the molecular
details of such interactions are understood only for a few proteins.
The pore-forming cholesterol-dependent cytolysins (CDCs) contrib-
ute to the pathogenic mechanisms of a large number of Gram-
positive bacteria. Cholesterol dependenceof the CDCmechanism is a
hallmark of these toxins, yet the identity of the CDC cholesterol
recognition motif has remained elusive. A detailed analysis of
membrane interactive structures at the tip of perfringolysin O
(PFO) domain 4 reveals that a threonine-leucine pair mediates CDC
recognition of and binding to membrane cholesterol. This motif is
conserved in all known CDCs and conservative changes in its
sequence or order are not well tolerated. Thus, the Thr-Leu pair
constitutes a common structural basis formediating CDC-cholesterol
recognition and binding, and deﬁnes a unique paradigm for mem-
brane cholesterol recognition by surface-binding proteins.
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Membrane cholesterol is important to a variety of patho-genic processes that include virus fusion and budding (1)
and the mechanisms of eukaryotic (2, 3) and prokaryotic toxins
(4–7). Whether cholesterol is bound directly by these proteins as
a receptor or it indirectly inﬂuences the binding or activity of
the protein at the membrane surface remains unknown. The
cholesterol-dependent cytolysins (CDCs) use cholesterol as
their receptor at the membrane surface (7) and contribute to
the pathogenesis of a large number of Gram-positive bacterial
pathogens (8). The CDC–sterol interaction initiates a cascade of
secondary and tertiary structural changes that lead to the for-
mation of a large oligomeric complex, and ultimately a pore in
the membrane of eukaryotic cells (9–13). Although signiﬁcant
progress has been made in understanding the assembly of the
CDC pore complex, the structural basis for recognition and
binding to cholesterol-rich membranes remains elusive.
Early studies with the Clostridium perfringens perfringolysin O
(PFO) suggested that the highly conserved tryptophan-rich
undecapeptide sequence at the base of domain 4 (14, 15) (Fig. S1)
mediated the PFO–cholesterol interaction. However, recent
studies by Soltani et al. (16) uncoupled cholesterol binding from
the undecapeptide and showed that the membrane insertion of
loops L1–L3 at the base of domain 4 was cholesterol dependent
(Fig. S1). These observations are also consistent with a lack of
conservation of the 3D structures of the undecapeptide in the
closely related CDCs PFO (17) and Bacillus anthracis anthrolysin
O (ALO) (18) (Fig. S1). These studies suggest the residues that
comprise the cholesterol recognition motif are located within L1–
L3 because these loops and the undecapeptide are the only
structures at the tip of domain 4 exposed to the nonpolar bilayer
core; the rest of the domain 4 surface is surrounded by water (19).
Cholesterol was thought to function as the sole CDC receptor
until the discovery of intermedilysin (ILY), a CDC from Strep-
tococcus intermedius. ILY was active only on human cells (20), a
feature seemingly inconsistent with the “cholesterol as receptor”
paradigm. Giddings et al. subsequently showed that ILY used
human CD59 (hCD59) as its membrane receptor (21), but pore
formation by ILY still required cholesterol (22). This enigma was
partially resolved by Soltani et al. (23), who showed that ILY
loops L1–L3 underwent a cholesterol-dependent membrane
insertion after ILY bound to hCD59. Removal of membrane
cholesterol prevented L1–L3 membrane insertion and appeared
to trap ILY in an oligomeric prepore state, although the struc-
tural basis for this defect was unclear.
The structuralmotif thatmediates the highly speciﬁc interaction
of CDCs with cholesterol remains unknown, as does the role of
cholesterol in the ILY mechanism. Herein, a detailed analysis
reveals that a remarkably simple motif, composed of a threonine–
leucine pair in loopL1, is conserved in all CDCs and is essential for
speciﬁcally recognizing cholesterol in themembrane and initiating
the cholesterol-dependent interaction of CDCs with membranes.
These studies also resolve the basis for the cholesterol dependence
of the ILY mechanism and provide a unifying structural basis for
the cholesterol dependence of CDCs whether they bind directly to
cholesterol or to a nonsterol receptor.
Results
Hemolytic and Binding Activity of PFO L1–L3 Alanine and Glycine
Mutants. The domain 4 surface is largely surrounded by water;
only loops L1–L3 and the undecapeptide at the tip of domain 4
interact with the bilayer (19). Because undecapeptide apparently
played no role in cholesterol recognition (16), the search for the
cholesterol recognition motif was focused on loops L1–L3. The
residues comprising L1, L2, and L3 (Table S1) were subjected to
scanningmutagenesiswith alanine and/or glycine.Eachmutantwas
screened for defects in hemolytic activity and in binding.Hemolytic
activity was lost by mutating L491, and severely impaired by
mutatingT490 (Fig. 1A), and PFObinding to liposomeswas greatly
reducedby the same twomutations (Fig. 1B).We therefore focused
our attention on T490 and L491 (Fig. 1C).
Double mutants were generated in which Thr-490 and Leu-491
were converted to either alanines or glycines. PFOT490A•L491A and
PFOT490G•L491G retained less than 0.03% of the wild-type PFO
hemolytic activity (Table 1). Similar results were observed when
glycine was substituted for the analogous residues of streptolysin
O (SLOT564G•L565G) and pneumolysin (PLYT459G•L460G) (Table
1), two PFO-like CDCs that bind directly to cholesterol-rich
membranes.
The substitution of the Thr-Leu pair does not appear to affect
the structure of PFO domain 4. Circular dichroism (Table S2)
and tryptophan emission spectra (Fig. S2) (six of the seven
tryptophan residues in PFO are in domain 4) of the mutants
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were not signiﬁcantly different from native PFO. Furthermore,
the sidechains of the four residues comprising loop L1 (Thr-489
to Tyr-492) extend into the aqueous solvent and do not form any
predicted interactions with residues outside of loop L1, sug-
gesting that their mutation is unlikely to perturb the structures of
nearby loops or undecapeptide.
Thr–Leu Mutant Binding to Cholesterol-Rich Liposomes, Human
Erythrocytes,and ImmobilizedCholesterol.Binding of PFOT490A•L491A,
PFOT490G•L491G, SLOT564G•L565G, and PLYT459G•L460G to choles-
terol-rich liposomes and human erythrocytes was examined by sur-
face plasmon resonance (SPR) (liposomes) and ﬂow cytometry
(erythrocytes), respectively. These mutants lacked detectable bind-
ing to cholesterol-rich liposomes and to human erythrocytes (Fig.
2A). Direct binding to cholesterol immobilized on a PVDF mem-
brane was not detected for any double mutants (Fig. 2B), consistent
with the SPR and ﬂow cytometry results. Taken together, these
observations suggest that the loop L1 Thr–Leu pair mediates the
recognition and binding of cholesterol at the membrane surface.
Loss of the cholesterol-dependent binding by PFOT490A•L491A
could not be restored to a detectable level either by second site
substitutions shown herein to increase binding of native PFO to
liposomes (alanine substituted Ser-399 and Asp-434, Fig.1) (Fig.
S3) or by substituting DOPC for POPC in liposomes containing
55 mol % cholesterol (Fig. S4), which is ≈25 mol % more cho-
lesterol than is require for maximal binding of PFO to these
liposomes (24, 25).
Structural Requirements of the CDC Cholesterol Recognition Motif.
The Thr–Leu pair is conserved in all known CDCs, which suggests
that even conservative substitutions are not tolerated. Sub-
stitution of serine for Thr-490 (PFOT490S), or of isoleucine or
valine for Leu-491 (PFOL491I, PFOL491V), did not restore hemo-
lytic activity to wild-type PFO levels, whereas double mutants
PFOT490S•L491I and PFOT490S•L491V were reduced in activity by
Fig. 1. Hemolytic and binding activity of PFO L1–3 loop mutants. Residues
within loops L1, L2, and L3 were systematically substituted with alanine and/
or glycine and assayed for changes in hemolytic activity (A) The change in
hemolytic activity is shown as the ratio of the HD50 (concentration of PFO or
mutant required for 50% hemolysis, see Methods for details) for each
mutant to that for wild-type PFO (HD50 = 0.34 nM). Hence, bar height is
inversely correlated with activity (n = 4 for each mutant hemolytic analysis).
Binding to cholesterol-rich liposomes was assessed by SPR. (B) Percent
binding of wild-type PFO is calculated by the equation ðRUWT −RUMUTRUWT Þ∗100,
where RUWT is the change in resonance units (RU) induced by passing 100 μL
wild-type PFO (900 nM) and RUMUT is the change in resonance units for each
mutant at the same concentration. In those cases where the mutant bound
better than wild-type PFO, the percent change was calculated from
ðRUMUTRUWT Þ∗100(n = 3 for each binding assay). Shown in C is the location of the
Thr-490•Leu-491 pair in the lower half of PFO domain 4 (for the complete
PFO structure refer to Fig. S1).
Table 1. Hemolytic activity of CDC derivatives containing
mutations in the cholesterol-binding motif
Toxin HD50 (nM) % WT activity
PFO 0.34 ± 0.1 100
PFOT490A•L491A >1410 <0.03
PFOT490G•L491G >1760 <0.02
SLO 0.8 ± 0.1 100
SLOT564G•L565G >1640 < 0.02
PLY 0.7 ± 0.3 100
PLYT459G•L460G >1890 <0.02
PFOT490S 3.2 ± 0.7 11
PFOL491I 1.5 ± 0.6 22
PFOL491V 1.9 ± 0.1 18
PFOT490S•L491I 83 ± 6 0.4
PFOT490S•L491V 92 ± 2 0.3
PFOT490L•L491T >1760 <0.02
Shown are the HD50 values for PFO, SLO, and PLY and their derivatives
containing mutants in the cholesterol recognition motif.
Fig. 2. Alanine or glycine substitution of the Thr–Leu pair of PFO, PLY, and
SLO abolishes binding. (A) Binding of PFO, PLY, SLO, and their derivatives to
cholesterol-rich liposomes was measured by SPR (Left column). Binding of
the same proteins to human RBCs was shown by ﬂow cytometry (Right
column). (B) A series of dot blots with twofold dilutions of cholesterol or
epicholesterol (starting at 65 nmols, indicated by the arrow) probed with the
same proteins and detected by antibody. Comparisons between binding of
wild type and its derivatives can be made, but binding comparisons between
CDCs are not valid due to differences in reactivity of the antibodies used for
their detection. c, cholesterol; e, epicholesterol; TL→AA and TL→GG, the
double alanine and double glycine mutants, respectively, of the Thr–Leu
pair. The binding analyses are representative of three experiments. GMF,
geometric mean ﬂuorescence.
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240-fold or more (Table 1). Binding to cholesterol-rich liposomes
and human erythrocytes was reduced for the single mutants and
was virtually undetectable for the double mutants (Fig. 3). Sim-
ilarly, binding of the single mutants to pure immobilized choles-
terol was less than that observed for wild-type PFO, whereas
binding was undetectable for the double mutants (Fig. 4).
Scrambling the linear sequence by inverting their positions
(PFOT490L•L491T) reduced hemolytic activity more than 5,000-
fold (Table 1), whereas binding to cholesterol-rich liposomes and
cells (Fig. 3) and to immobilized cholesterol was undetectable
(Fig. 4). The structural arrangement of the Thr–Leu motif is
therefore relatively inﬂexible, consistent with its conservation in
all CDCs and its critical role in the speciﬁc recognition and
binding of membrane cholesterol.
Role of the Thr–Leu Pair in the Intermedilysin Pore-FormingMechanism.
Intermedilysin (ILY) ﬁrst binds to its cellular receptor, hCD59
(21), and then undergoes a cholesterol-dependent insertion of its
L1–L3 loops (16). Because hCD59 anchored ILY to the mem-
brane, it was unclear why the ILY pore-forming mechanism
remained sensitive to the cholesterol-dependent insertion of these
loops. We recently showed, however, that ILY disengages from
hCD59 during the prepore-to-pore transition (26). If the Thr–Leu
pair is unable to initiate the cholesterol-dependent membrane
interaction of loops L1–L3 we hypothesized that ILY would lose
contact with the cell surface when it disengages from hCD59.
To test this hypothesis, we compared the membrane binding of
native ILYand ILYT517G•L518G in twodifferent states: amonomer-
locked (ML) state that prevents disengagement of ILY from its
receptor and the nonlocked state that allows ILY to undergo all
conformational changes necessary to form a pore. A disulﬁde bond
was introduced between β-strands 4 and 5 of the domain 3 core
β-sheet, which prevents the disengagement of β5 from β4, a struc-
tural transition that is necessary to convert monomers into
oligomers (11, 26). As predicted, ILYML and wild-type ILY bound
to erythrocytes (Fig. 5A). Also, the monomer-locked version of
ILYT517G•L518G (ILYT517G•L518G(ML)) remained cell bound
because it cannot undergo the structural transitions that disengage
it fromhCD59 (Fig. 5B). Consistent with our hypothesis, binding of
ILYT517G•L518G to erythrocytes wasundetectable byﬂowcytometry
(Fig. 5B). Hence, as ILYT517G•L518G disengages receptor it looses
contact with themembrane if it is unable to initiate the cholesterol-
dependent interaction of L1–L3. A parallel set of experiments was
also carried out with PFO. PFO in its native or monomer-locked
states binds to membrane (Fig. 5A). Since PFO requires the Thr–
Leu pair to initiate contact with cholesterol-rich membranes,
PFOT490G•L491G did not bind in either its monomer-locked or
nonlocked state (Fig. 5B).
The ﬂow cytometry studies were conﬁrmed by SDS/PAGE
analysis of the soluble and membrane-bound fractions of human
Fig. 3. Structural requirements of the cholesterol recognition motif. SPR
analysis of binding for the various PFO mutants to cholesterol-rich liposomes
is shown in the Left column. Flow cytometric analysis of binding to human
erythrocytes is shown in the Right column. The SPR and ﬂow cytometry
results are representative of three or more experiments.
Fig. 4. Binding of PFO mutants to immobilized cholesterol. The EC50 for
PFOT490S, PFOL491I, and PFOL491V were compared to the EC50 for PFO. Upper
panel is a representative dot blot that shows binding of each toxin to the
various cholesterol concentrations (see Fig. 3 andMethods for details). In the
table Below are the EC50 values and standard errors (n = 7) calculated from
densitometric analysis of the dots and the fold increase in EC50 for each
mutant. The double mutants PFOT490S•L491I, PFOT490S•L491V, and PFOT490L•L491T
did not exhibit detectable binding to the immobilized cholesterol so an EC50
value was not determined (ND). The absolute concentrations of bound
cholesterol on the PVDF membrane are not known; the values are used only
to compare the relative binding of PFO and its derivatives (EC50Mut/EC50WT).
Fig. 5. The Thr–Leu pair is necessary to maintain ILY-membrane contact
during pore formation. Binding by ﬂow cytometry of wild-type ILY and
monomer-locked ILY (ILYML) to human erythrocytes (A) is compared with the
Thr–Leu glycine-substituted mutant in nonlocked (ILYT517G•L518G) and
monomer-locked background (ILYT517G•L518G(ML)) (B). Also shown are the
corresponding analyses of nonlocked and monomer-locked versions of PFO
and PFOT490G•L491G (A and B, Right). (C) SDS/PAGE and Western blot analysis
showing ILY, ILYML, and ILYT517G•L518G(ML) are present in both pellet (P) and
supernatant (S) fractions (due to receptor saturation with excess toxin)
whereas the ILY double glycine mutant is found exclusively in the super-
natant fraction. The ﬂow cytometry and SDS/PAGE analyses are repre-
sentative of three experiments. *ILYML-induced erythrocyte agglutination at
this and higher concentrations, which depressed the ﬂuorescence signal.
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erythrocytes treatedwith ILYand its derivatives. Consistent with the
ﬂow cytometry results ILY, ILYML, and ILYT517G•L518G(ML) were
associated with the pellet and supernatant fractions due to receptor
saturation with excess toxin (Fig. 5C). As predicted, ILYT517G•L518G
was detected exclusively in the supernatant fraction.
Discussion
The strict requirement of CDC pore formation for membrane
cholesterol has been known for over 50 years (27). Membranes
that lack or are signiﬁcantly depleted of cholesterol are not
susceptible to the pore-forming activity of these toxins. For many
years, cholesterol recognition was attributed to the highly con-
served Trp-rich undecapeptide of the CDCs (14, 15), but recent
studies by Soltani et al. (16) suggested that the cholesterol rec-
ognition motif resided within loops L1–L3, not the undecapep-
tide. The current studies have now discovered that only two
residues, a Thr–Leu pair in Loop L1, are essential for CDC
cholesterol recognition and binding in cholesterol-rich lip-
osomes, in natural cell membranes, and in pure immobilized
cholesterol. This motif is shown here to be critical for cholesterol
recognition for four different CDCs, but its strict conservation in
all CDC sequences suggests that the Thr–Leu pair functions
similarly for all members of the family. The CDC cholesterol
recognition motif is remarkably simple, but highly speciﬁc for
cholesterol, and thus serves as a unique structural paradigm for
cholesterol recognition motifs.
The Thr–Leu pair interacts speciﬁcally with cholesterol instead
of preferentially inserting into cholesterol-rich domains. Inver-
sion of the Thr–Leu sequence eliminated detectable binding, even
though the free energy of partitioning Leu–Thr into the bilayer
would be the same as for Thr–Leu. Also, conservative mutation of
the Thr–Leu pair was not well tolerated, suggesting that the
structure and orientation of the Thr–Leu sidechains are impor-
tant factors in this recognition. It is unlikely that residues from the
other two loops are involved in cholesterol recognition to any
signiﬁcant extent, although they likely contribute to the binding
energy by partitioning their sidechains into the bilayer. Residues
in L3 are not conserved, whereas L2 residue sidechains are either
buried in the domain 4 core (Tyr-402 and Ala-404), lack a side-
chain (Gly-401), or their substitution with alanine or glycine did
not signiﬁcantly affect binding (Ala-401 and Val-403). Ser-399
(L2) and Asp-434 (L3) increased binding of PFO, but placing
these two mutants into the PFOT490A•L491A background did not
restore any detectable binding. Also, it is unlikely that substitution
of the TL pair affects the structure of loops L2 and L3 because the
residues of loop L1 (Thr–Thr–Leu–Tyr) extend into the solvent
and their sidechains do not form any predicted interactions with
residues outside of L1, consistent with measurements that show
no detectable perturbations of the domain 4 structure of these
mutants. Hence, the Thr–Leu pair in the context of L1 appears to
confer speciﬁcity for membrane cholesterol, whereas the sub-
sequent membrane insertion of residues in loops 2 and 3
strengthen the interaction with the membrane.
The only other well-characterized sterol-binding motif is the
eukaryotic cholesterol recognition amino acid consensus (CRAC)
motif (reviewed in ref. 28). Signiﬁcant structural and operational
differences, however, exist between the CDC cholesterol recog-
nition motif and the CRAC motif. The CRAC motif (L/V-X(1-5)-
Y-X(1-5)-R/K) is typically located adjacent to a transmembrane
α-helix that positions this sequence within the nonpolar core of the
bilayer where it can form contacts along the length of the choles-
terol molecule (29). In contrast, the CDC Thr–Leu pair must
recognize speciﬁc features of cholesterol at or near the membrane
surface to initiate the cholesterol-dependent interaction of
theCDCwith the cell. Previous studies havedemonstrated that the
3-hydroxy headgroup of cholesterol in the 3-β stereoisomer con-
ﬁguration is required for recognition by the CDCs as well as a
structurally intact A ring and iso-octyl hydrocarbon chain at C17
(30–33). Cholesterol is a planarmolecule that packs parallel to the
phospholipid acyl chains and adopts a nearly perpendicular ori-
entation to the cell surface (34), with the 3-β-hydroxy group at
the surface and the iso-octyl chain near the bilayer core. The 3-
β-hydroxyl of cholesterol appears to serve as an important factor
for stereo-speciﬁc binding of cholesterol, although it is unlikely to
be the only component of the cholesterol headgroup to contribute
to this interaction with the Thr–Leu pair. The stereo-speciﬁcity of
the binding presumably results directly from the conformation of
the Thr–Leu pair in the L1 loop and the consequent steric
requirements of aligning the hydrogen bond donor(s) and
acceptor(s) while simultaneously juxtaposing and maximizing
multiple van der Waals contacts. It is also likely the structure of
loop L1 and correct presentation of the Thr–Leu pair are neces-
sary for cholesterol recognition. Thus, not all Thr–Leu pairs would
be capable ofmediating such an interaction. It is unlikely that theC
and D rings and the iso-octyl hydrocarbon chain at C17 directly
participate in CDC recognition because they reside far inside the
bilayer core and are therefore not accessible to the Thr–Leu pair.
Their structures, however, can affect the packing and orientation
of the cholesterol molecule in the bilayer (34), which may indi-
rectly affect the presentation of the cholesterol headgroup at the
membrane surface.
Once the Thr–Leu pair recognizes cholesterol, the interaction
of the CDC monomer with the membrane is furthered strength-
ened by the membrane insertion of additional residues of loops
L1–L3 and residues of the undecapeptide (19, 35). The Thr–Leu
interaction with cholesterol may also elicit rearrangement of the
L1 polypeptide that then is transmitted throughout the protein.
We previously observed that domain 4 binding corresponds to
structural changes in PFO domain 3 that is located more than 70
Å above the membrane surface (11, 36). The change in the
domain 3 structure leads to oligomerization of membrane bound
monomers into the prepore, which then makes the transition to
the β-barrel pore (11, 13).
ILY and the recently identiﬁed CDC from Gardnerella vagi-
nalis, vaginolysin (VLY) do not bind directly to cholesterol but
instead bind the protein receptor hCD59 (21, 37). Yet the pore-
forming activity of both CDCs remains cholesterol dependent.
Recent studies by Lachapelle et al. (26) showed that ILY dis-
engages from hCD59 during the transition of oligomeric ILY
from the prepore to pore state. We show here that the Thr–Leu
pair of ILY must initiate a cholesterol-dependent interaction
with the membrane, otherwise it loses contact with the mem-
brane surface as individual monomers within the prepore com-
plex disengage from the receptor during the prepore to pore
transition. Because loops L1–L3 only insert in a cholesterol-
dependent fashion after ILY binds its receptor hCD59 (16), it
presumably orients loops L1–L3 and the undecapeptide near the
membrane surface.
In conclusion, a remarkably simple structure composed of a
threonine–leucine pair functions as the cholesterol recognition
motif of theCDCs.Themembrane binding ofmany other bacterial
and eukaryotic toxins is cholesterol dependent, but their choles-
terol recognitionmotif is unknown. Therefore it will be interesting
to determine how widespread the Thr–Leu recognition is among
other cholesterol-dependent membrane active proteins.
Methods
Bacterial Strains, Plasmids, and Chemicals. The genes for PFO, SLO, and ILY
were cloned into pTrcHisA (Invitrogen) as described previously (23). The gene
for PLY was cloned into pQE-30 (a generous gift from R. Malley). All
mutations in PFO were made in the cysteine-less background (PFOC459A).
Mutations in other CDCs were generated in native SLO and PLY (both con-
taining the native cysteine) and ILY (naturally cysteine-less) backgrounds. All
chemicals and enzymes were obtained from Sigma, VWR, and Research
Organics. All ﬂuorescent probes were obtained from Molecular Probes
(Invitrogen). Primary antibodies, anti-Xpress and anti-PLY (NCL-SPNm), were
obtained from Invitrogen and Novocastra, respectively. Polyclonal anti-PFO
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antibody was afﬁnity puriﬁed from hyperimmune rabbit serum. Secondary
antibodies, goat anti-mouse labeled with ﬂuorescein isothiocyanate (FITC)
and goat anti-rabbit-FITC were obtained from Abcam and goat anti-mouse-
HRP and goat anti-rabbit-HRP were obtained from Biorad. Sterols were
obtained from Steraloids.
Generation and Puriﬁcation of Toxin Derivatives. Various amino acid sub-
stitutions were made in PFO, SLO, PLY, and ILY using PCR QuikChange
mutagenesis (Stratagene) and veriﬁed by DNA sequencing analysis per-
formed by the Oklahoma Medical Research Foundation Core DNA
Sequencing Facility. The expression and puriﬁcation of recombinant toxins
and derivatives from Escherichia coli were carried out as described (23).
Puriﬁed protein was dialyzed into buffer [100 mM NaCl, 50 mM HEPES; (pH
7.5)] overnight at 4 °C and stored in 50 μM TCEP (except for monomer-locked
derivatives) and 10% (vol/vol) sterile glycerol at −80 °C.
Hemolytic Activity and Trypsin Sensitivity of Toxins and Their Derivatives. The
pore-forming activity of each toxin and derivative was measured using a
hemolytic titration assay as previously described (13). The trypsin sensitivity
of each mutant was examined as previously described (16) and compared to
that of native toxin. No signiﬁcant difference in cleavage patterns was noted
in the various mutants and wild-type CDCs.
Liposome Preparation. Liposomes containing 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC; Avanti Polar Lipids) or 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and cholesterol at a molar ratio of 45:55 were
prepared as described (13).
SPR Analysis. SPR was measured with a BIAcore 3000 system (Oklahoma
Medical Research Foundation) using a L1 sensor chip (BIAcore). To prepare
the L1 chip with liposomes, 10 μL of 20 mM CHAPS was injected at a ﬂow rate
of 10 μL/min. Liposomes (0.5 mM ﬁnal lipid concentration) were then
injected at the same ﬂow rate for 15 min. After injection of liposomes, 50
mM NaOH was injected for 3 min, followed by injection of 0.1 mg/mL BSA
for 1 min. All injections were performed at 25 °C. The L1 chip was regen-
erated and stripped of liposomes by repeated injections of 20 mM CHAPS
and 50 mM NaOH until original resonance units (RU) readings were reached.
No loss of sensor chip binding capacity resulted from regeneration.
Binding analyses were performed in HBS [100 mM NaCl, 50 mM HEPES (pH
7.5)] at 25 °C. Nine consecutive 50-μL injections of PFO or derivatives (100 ng
per injection), SLO or derivatives (25 ng per injection), or PLY or derivatives
(25 ng per injection) were passed over the liposome-coated chip at a ﬂow
rate of 10 μL/min. No change in the RU was observed due to buffer.
Flow Cytometry. Twofold serial dilutions of the various toxins or their
derivatives were incubated with washed erythrocytes (1 × 106 cells) in PBS for
1 h at 4 °C (reaction volume 100 μL) to minimize cell lysis. Primary antibody
(anti-Xpress or anti-PLY) was added 1:100 in 50 μL PBS containing 0.1% (wt/
vol) BSA and incubated 30 min at 4 °C. Secondary antibody (goat anti-
mouse-FITC) was added 1:100 in 50 μL PBS containing 0.1% (wt/vol) BSA and
incubated 30 min at 4 °C. Cells were pelleted (14,000 × g for 10 min) and
washed twice with ice-cold PBS. Samples were then brought to a ﬁnal vol-
ume of 500 μL with ice-cold PBS and analyzed by a FACSCalibur ﬂow
cytometer (University of Oklahoma Health Sciences Center), gating on both
live and dead cells. The emission wavelength was 530 nm, and the excitation
was 488 nm with a bandpass of 30 nm.
SDS/PAGE and Western Blot. ILY or its derivatives (142 nM) were incubated
with huRBCs at 37 °C for 45 min, and each sample was centrifuged at 15,000
rpm for 15 min to separate cell-bound and soluble ILY. Each pellet was
solubilized with 25% (wt/vol) SDS, boiled for 5 min and the proteins sepa-
rated on a 10% SDS/PAGE gel (125 V for 70 min), and transferred to nitro-
cellulose. The blot was incubated for 1 h with blot wash [20 mM Tris-HCl (pH
8.0), 0.3 M NaCl, 0.5% (vol/vol) Tween 20] made 3% (wt/vol) in dry nonfat
milk and 7.7 mM in sodium azide (blocking buffer), and incubated with anti-
Xpress primary antibody overnight at room temperature. Blots were washed
three times with blot wash and incubated with goat anti-mouse-HRP for 45
min, washed three more times, and treated with ECL Western Blotting
Detection kit (Amersham). Blots were exposed to X-ray ﬁlm (Life Science
Products) to detect the ILY bands.
Cholesterol Dot Blot Analysis. Binding of the CDCs and their derivatives to
pure cholesterol was determined by dot blot. A PVDF membrane was wetted
with 100% methanol and then washed in 25 mL PBS buffer before placing it
into a Hybri-dot Manifold apparatus (Bethesda Research Labs) to which
cholesterol and epicholesterol stocks (in 100% ethanol) were serially diluted
(in PBS) from 65 nmol to 16 pmol in each set of 12wells. After 30min the sterol
solution was pulled through the membrane by vacuum. The membrane was
removed from the manifold and blocked in blocking buffer (as for the
Western blot, above) for 1 h. Each set of 12 wells was cut into strips and each
strip was incubated with the various CDCs or their derivatives (5 μg/mL in a
total of 10 mL blocking buffer) for 1 h at room temperature. Blots were
washed with blot wash (25 mL) three times and incubated with primary
antibody (1:1,000 in blocking buffer) for 30 min at room temperature and
then removed by washing the blot three times with 25 mL of blot wash each
time. Secondary antibody conjugated to horseradish peroxidase was added
to the membrane (1:2,000 in blocking buffer), incubated for 15 min at room
temperature, and unbound antibody was removed as done for the primary
antibody. Bound toxin was visualized by developing the blot as done for the
Western blot. To quantify binding, the ﬁlm was scanned and the optical
density of the dots determined using Image J analysis software (38). The EC50
(effective concentration of cholesterol for 50% binding of each toxin) was
determined using Prism software (GraphPad Software, Inc.).
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